Patents by Inventor Matthew G. Vander Heiden

Matthew G. Vander Heiden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS
    Publication number: 20220249534
    Abstract: The present disclosure provides methods for inhibiting cell proliferation, inducing differentiation, and inducing replication stress in a cancer cell. The present disclosure also provides methods for treating a cancer in a patient. Various methods of the disclosure include contacting a cancer cell with, or administering to a patient having cancer, an agent that can change the internal baseline ratio of purine:pyrimidine in the cancer cell.
    Type: Application
    Filed: February 8, 2022
    Publication date: August 11, 2022
    Inventors: Matthew G. Vander Heiden, Peggy P. Hsu, Frances Flewelling Diehl, David B. Sykes
  • Inhibitors of pyruvate kinase and methods of treating disease
    Patent number: 8877791
    Abstract: The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: November 4, 2014
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Lewis Cantley, Matthew G. Vander Heiden, Heather R. Christofk
  • Activators of pyruvate kinase M2 and methods of treating disease
    Patent number: 8552050
    Abstract: The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: October 8, 2013
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Lewis C. Cantley, Matthew G. Vander Heiden, Heather R. Christofk
  • ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE
    Publication number: 20110046083
    Abstract: The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders.
    Type: Application
    Filed: August 18, 2008
    Publication date: February 24, 2011
    Applicant: Beth Israel Deaconess Medical Center
    Inventors: Lewis C. Cantley, Matthew G. Vander Heiden, Heather R. Christofk